The company now needs to carry out separate phase 2s of its G12D inhibitor VS-7375.
ApexOnco Front Page
Recent articles
The group is pitting its anti-CD19 T-cell engager MK-1045 head-to-head against Blincyto.
Dispatch Bio’s virus therapy DV-10 enters phase 1.
The QCS assay for TROP2 is being implemented more broadly, at the cost of further readout delays.
ERAS-0015 data look good, but the company is punished for a pneumonitis death.
Unlike the US FDA, the CHMP doesn't recommend approval for pre-chemo prostate cancer.
The Companion-002 trial of tovecimig fails to show an overall survival benefit versus chemo.
The move shows a gap developing between Relay and Lilly in PI3Kα inhibition.
